Evidence map›Paper›PMID 29577674›Full record

Trial reportCancer medicine2018

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.

Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo-Youn Cho, Dae-Young Kim, Kyoo-Hyung Lee, Hyeong-Joon Kim, Jae-Sook Ahn, Yeo-Kyeoung Kim, Jinny Park and 22 more

Open access · goldAbstract readClinical Trial, Phase IVMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 19 institutions in 2 countries.

Junghoon ShinDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-6834-7217
Youngil KohDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Seo Hyun YoonDepartment of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Korea.
Joo-Youn ChoDepartment of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul, Korea.
Dae-Young KimDepartment of Internal Medicine, Asan Medical Center, Seoul, Korea.
Kyoo-Hyung LeeDepartment of Internal Medicine, Asan Medical Center, Seoul, Korea.
Hyeong-Joon KimDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Jae-Sook AhnDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Yeo-Kyeoung KimDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Jinny ParkDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Sang-Kyun SohnDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Joon Ho MoonDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Yoo Jin LeeDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Seonghae YoonClinical Trials Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Jeong-Ok LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
June-Won CheongDepartment of Internal Medicine, Severance Hospital, Seoul, Korea.
Kyoung Ha KimDepartment of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Sung-Hyun KimDepartment of Internal Medicine, Dong-A University Hospital, Busan, Korea.
Hoon-Gu KimDepartment of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.
Hawk KimDepartment of Internal Medicine, Ulsan University Hospital, Ulsan, Korea.
Seung-Hyun NamDepartment of Internal Medicine, VHS Medical Center, Seoul, Korea.
Young Rok DoDepartment of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Sang-Gon ParkDepartment of Internal Medicine, Chosun University Hospital, Gwangju, Korea.
Seong Kyu ParkDepartment of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Sung Hwa BaeDepartment of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
Hun Ho SongDepartment of Internal Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea.
Dong-Yeop ShinDepartment of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.ORCID 0000-0003-1753-8846
Doyeun OhDepartment of Internal Medicine, CHA Bundang Medical Center, Seongnam, Korea.ORCID 0000-0002-6981-3144
Min Kyoung KimDepartment of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Chul Won JungDepartment of Internal Medicine, Samsung Medical Center, Seoul, Korea.
Seonyang ParkDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Inho KimDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Seoul National University Hospital · KRGyeongsang National University Hospital · KRKyungpook National University Hospital · KRSoonchunhyang University · KRAsan Medical Center · KRChonnam National University Hwasun Hospital · KRCHA University Bundang Medical Center · KRDaegu Catholic University Medical Center · KRDong-A University Hospital · KRGachon University Gil Medical Center · KRKangdong Sacred Heart Hospital · KRKeimyung University Dongsan Medical Center · KRNational Cancer Center · USSamsung Medical Center · KRSeoul Medical Center · KRSeoul National University Bundang Hospital · KRSeverance Hospital · KRSoonchunhyang University Hospital Seoul · KRYeungnam University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML-CP). We investigated the 2-year efficacy and safety of nilotinib and their relationships with plasma nilotinib concentrations (PNCs). In this open-label, multi-institutional phase 4 study, 110 Philadelphia chromosome-positive CML-CP patients were treated with nilotinib at a starting dose of 300 mg twice daily. Molecular responses (MRs) and AEs were monitored for up to 24 months. The 24-month cumulative MR

Indexed as

AdultAgedAged, 80 and overChromatography, LiquidDrug Administration ScheduleFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPyrimidinesRepublic of KoreaTandem Mass SpectrometryTreatment OutcomenilotinibPyrimidinesCMLmolecular responsenilotinibprognosis

Identifiers

PMID29577674
PMCPMC5943463
OpenAlexW2791143140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.